Novo Nordisk Invented the Obesity Trade. The Market Just Priced It for Losing.
Eli Lilly is worth more than $1 trillion. Novo Nordisk trades near its 52-week low with an FDA decision on CagriSema due before year-end. Inside the pill war that split the obesity trade in two — and the catalyst that could reset it.
The two companies that own the obesity drug market have never been further apart. Eli Lilly trades around $1,170, up roughly 38% over the past year, with a market value that crossed the trillion-dollar mark. Novo Nordisk — the company that invented this market, that made "Ozempic" a verb — trades near $38, down about 37% over the same twelve months and more than 40% below its 52-week high. Lilly is now worth roughly six times the Danish company that started it all.
That gap is not a quirk of sentiment. It is the market's verdict on a two-year competitive war that Novo keeps losing — and it has hardened just as Novo approaches the single event that could change the story: a U.S. FDA decision on CagriSema, its next-generation obesity drug, due in the fourth quarter of this year.
The Scoreboard
Start with the numbers both companies printed in August. Lilly's second-quarter revenue jumped 48% to almost $23 billion, crushing the roughly $20.6 billion consensus, and management raised full-year guidance to $85–87 billion. The engine is tirzepatide — sold as Mounjaro for diabetes and Zepbound for obesity — which topped $36 billion in sales last year and is now the best-selling drug in the world.
Novo's print, delivered a day earlier, moved the stock 6% in the other direction. The company guided full-year sales at constant exchange rates to somewhere between flat and down 6% — an improvement, remarkably, on its prior forecast of a 4–12% decline. One member of the duopoly is guiding to roughly $86 billion and growing; the other is guiding to shrink.
The Pill War
The sharpest front in this war opened this year, in tablet form. Novo won U.S. approval for an oral version of Wegovy in late December 2025 and got it to market with a three-month head start — one of the fastest drug launches on record. Lilly answered in April with Foundayo, the pill form of orforglipron, launching at $149 a month for the starting dose for self-pay patients — matching Novo's price to the dollar — with savings-card pricing as low as $25 a month for some insured patients and same-day Amazon Pharmacy delivery in nearly 3,000 cities.
The distribution landscape shifted again on July 1, when Medicare coverage of GLP-1 medicines expanded under the pricing deal both companies struck with Washington to avoid tariffs — co-pays for some patients now run as little as $50 a month. Lilly CEO David Ricks has argued the pills widen the market rather than cannibalize the injectables, telling CNBC in January that almost everyone starting on the Wegovy pill was trying a GLP-1 for the first time.
So far, the orals have been a race of disappointments — but asymmetrically punished ones. In the second quarter, the Wegovy pill sold about $494 million (3.2 billion Danish kroner), short of the 3.6 billion kroner analysts expected. Foundayo also missed, at $98 million against a $104 million estimate. Novo — the clear leader in oral obesity sales — fell on its miss. Lilly rose 2% on its report. When one company is priced for dominance and the other for decline, the same headline produces opposite reactions.
Convenience may decide the next leg: oral Wegovy must be taken first thing in the morning on an empty stomach, half an hour before food or water. Foundayo can be taken any time, no restrictions — and neither drug has faced the other in a head-to-head trial.
The Last Pillar
Which brings us to CagriSema, the asset Novo's recovery case rests on. It is a once-weekly injection combining semaglutide — the molecule behind Ozempic and Wegovy — with cagrilintide, a long-acting amylin analog. Novo filed it with the FDA in December 2025 for chronic weight management; the agency's decision is expected this quarter.
The trial record is genuinely mixed. In its pivotal REDEFINE program, CagriSema produced up to 22.7% weight loss — numbers that would have seemed miraculous five years ago. But in August, Novo disclosed that CagriSema failed to show non-inferiority to Lilly's tirzepatide on blood-sugar control in a head-to-head diabetes trial, and the stock sank again. At its Capital Markets Day on September 21, Novo presented fresh topline data it framed as redemption — a slight edge over tirzepatide on HbA1c reduction (1.71 vs. 1.67 percentage points, per the company) and 12.4% weight loss at 60 weeks in diabetic adults — and the market's answer was an 8% single-day decline. Novo shares now sit within sight of their 52-week low.
That is the setup: a company trading like a melting ice cube, weeks away from a binary regulatory event on the one asset that could rebuild its growth story. The question that matters for investors isn't whether CagriSema gets approved. It's whether approval even matters at this price — and what, specifically, would have to happen for the widest valuation gap in big pharma to start closing.
Get the next briefing free in your inbox: Join AlphaBriefing
The rest of this briefing is for paid members: the full Q4 catalyst calendar for both stocks, the three CagriSema decision scenarios and how each likely reprices Novo, the asymmetry case at the 52-week low — and the specific signposts that would flip our read from value trap to turnaround.
AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish — the analysis private intel clients pay four figures for, at a fraction of that.